This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yonou, H. Articles by Ochiai, A. Search for Related Content PubMed PubMed Citation Articles by Yonou, H. Articles by Ochiai, A.

Osteoprotegerin/Osteoclastogenesis Inhibitory Factor Decreases Human Prostate Cancer Burden in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice¹

Pathology Division, National Cancer Center Research Institute East, Chiba 277-8577 [H. Y., N. K., M. G., T. K., T. Y., T. Has., A. O.]; Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba 277-8577 [K. N.]; and Department of Urology, University of the Ryukyus, Okinawa 903-0215 [H. Y., T. Hat., Y. O.], Japan

Human prostate cancer frequently metastasizes to bone, where it gives rise to osteoblastic bone metastases with an underlying osteoclastic component and subsequent bone pain. However, the importance of osteoclastogenesis in the development of prostate cancer bone lesions in humans is unclear. Osteoprotegerin/osteoclastogenesis inhibitory factor (OCIF) is a member of the tumor necrosis factor receptor family and a novel secreted protein, and it is a negative regulator of osteoclast differentiation, activation, and survival both in vitro and in vivo. In the present study we used a model in which human LNCaP prostate cancer cells that give rise to osteoblastic bone tumors were injected directly into the intramedullary space of human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice to investigate whether the new bone-resorption inhibitor osteoprotegerin/OCIF would inhibit the development of new bone tumors and the progression of established osteoblastic bone tumors. The mice were given consecutive daily s.c. injections of recombinant human OCIF (rhOCIF; 100 µg/mouse/day) for 2 weeks starting either immediately or 2 weeks after injection of the LNCaP cells. In both protocols, rhOCIF markedly inhibited both the development of bone tumors and the progression of established bone tumor foci quantified by histological examination. Histomorphometrical analysis revealed that rhOCIF markedly reduced the number of osteoclasts and the size of the tumors at the bone sites, but that it had no effect on the local growth of s.c. LNCaP tumors or on LNCaP cell proliferation in culture. These findings demonstrate that osteoclasts play an important role in bone tumor by prostate cancer, and that rhOCIF decreases the LNCaP prostate cancer burden selectively in bone, suppresses the progression of established tumor lesions, and prevents the development of new lesions. These results suggest that inhibition of osteoclastic bone resorption may be an effective therapy for the treatment of prostate cancer that has colonized bone.

This article has been cited by other articles:

				F. Lamoureux, G. Picarda, J. Rousseau, C. Gourden, S. Battaglia, C. Charrier, B. Pitard, D. Heymann, and F. Redini Therapeutic efficacy of soluble receptor activator of nuclear factor-{kappa}B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma Mol. Cancer Ther., October 1, 2008; 7(10): 3389 - 3398. [Abstract] [Full Text] [PDF]

				R. E. Miller, M. Roudier, J. Jones, A. Armstrong, J. Canon, and W. C. Dougall RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis Mol. Cancer Ther., July 1, 2008; 7(7): 2160 - 2169. [Abstract] [Full Text] [PDF]

				A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]

				C. Le Gall, A. Bellahcene, E. Bonnelye, J. A. Gasser, V. Castronovo, J. Green, J. Zimmermann, and P. Clezardin A Cathepsin K Inhibitor Reduces Breast Cancer Induced Osteolysis and Skeletal Tumor Burden Cancer Res., October 15, 2007; 67(20): 9894 - 9902. [Abstract] [Full Text] [PDF]

				F. Lamoureux, P. Richard, Y. Wittrant, S. Battaglia, P. Pilet, V. Trichet, F. Blanchard, F. Gouin, B. Pitard, D. Heymann, et al. Therapeutic Relevance of Osteoprotegerin Gene Therapy in Osteosarcoma: Blockade of the Vicious Cycle between Tumor Cell Proliferation and Bone Resorption Cancer Res., August 1, 2007; 67(15): 7308 - 7318. [Abstract] [Full Text] [PDF]

				Y. Lu, Z. Cai, G. Xiao, E. T. Keller, A. Mizokami, Z. Yao, G. D. Roodman, and J. Zhang Monocyte Chemotactic Protein-1 Mediates Prostate Cancer-Induced Bone Resorption Cancer Res., April 15, 2007; 67(8): 3646 - 3653. [Abstract] [Full Text] [PDF]

				R. L. Vessella and E. Corey Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s. [Abstract] [Full Text] [PDF]

				Y. Li, O. Kucuk, M. Hussain, J. Abrams, M. L. Cher, and F. H. Sarkar Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer. Cancer Res., May 1, 2006; 66(9): 4816 - 4825. [Abstract] [Full Text] [PDF]

				E. Corey, L. G. Brown, J. A. Kiefer, J. E. Quinn, T. E.M. Pitts, J. M. Blair, and R. L. Vessella Osteoprotegerin in Prostate Cancer Bone Metastasis Cancer Res., March 1, 2005; 65(5): 1710 - 1718. [Abstract] [Full Text] [PDF]

				J. Zhang, J. Dai, Z. Yao, Y. Lu, W. Dougall, and E. T. Keller Soluble Receptor Activator of Nuclear Factor {kappa}B Fc Diminishes Prostate Cancer Progression in Bone Cancer Res., November 15, 2003; 63(22): 7883 - 7890. [Abstract] [Full Text] [PDF]